Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 700Breast Neoplasms 630Neoplasms 583Leukemia, Myeloid, Acute 481Colorectal Neoplasms 457Multiple Myeloma 444Melanoma 426Prostatic Neoplasms 383Neoplasm Metastasis 374Pancreatic Neoplasms 364Recurrence 350Lymphoma 340Ovarian Neoplasms 325Lung Neoplasms 298Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 276Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 231Squamous Cell Carcinoma of Head and Neck 220Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 210Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Lymphoma, Mantle-Cell 167Triple Negative Breast Neoplasms 166

Interventions

Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Disulfides 1Bevacizumab 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × Platinum-Refractory Fallopian Tube Carcinoma × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡